Publication:
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsKefeli, Umut; Benekli, Mustafa; Sevinc, Alper; Yildiz, Ramazan; Kaplan, Muhammed Ali; Ciltas, Aydin; Balakan, Ozan; Isikdogan, Abdurrahman; Coskun, Ugur; Dane, Faysal; Harputluoglu, Hakan; Karaca, Halit; Yazilitas, Dogan; Durnali, Ayse; Kaya, Ali Osman; Demirci, Umut; Gumus, Mahmut; Buyukberber, Suleyman
dc.date.accessioned2022-03-14T10:56:31Z
dc.date.available2022-03-14T10:56:31Z
dc.date.issued2013-08
dc.description.abstractSorafenib is a multi-targeted tyrosine kinase receptor inhibitor used to treat patients with advanced gastrointestinal stromal tumors (GISTs). The present study evaluated the efficacy and tolerability of sorafenib therapy for patients with GISTs. Between January 2001 and November 2012, 25 patients, from multiple centers, who had received sorafenib as the third-or fourth-line treatment for GISTs were investigated retrospectively. In total, 17 patients were male and eight were female. The median age was 54.0 years (range, 16-82 years). From the patients, 21 received imatinib for longer than six months and four received it for less than six months. The clinical benefit rate of sorafenib was 40.0%. Treatment-related adverse events were reported in 72% of patients. These adverse events were generally mild to moderate in intensity. The median progression-free survival (PFS) and overall survival (OS) times of the patients who received sorafenib were 7.2 and 15.2 months, respectively. The duration of imatinib usage was an independent prognostic factor for PFS and OS. Sorafenib is an effective treatment in patients with GISTs showing a clinical benefit rate of 40.0% and an acceptable tolerability.
dc.identifier.doi10.3892/ol.2013.1408
dc.identifier.eissn1792-1082
dc.identifier.issn1792-1074
dc.identifier.pubmed24137379
dc.identifier.urihttps://hdl.handle.net/11424/245539
dc.identifier.wosWOS:000322381000060
dc.language.isoeng
dc.publisherSPANDIDOS PUBL LTD
dc.relation.ispartofONCOLOGY LETTERS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectsorafenib
dc.subjectgastrointestinal stromal tumors
dc.subjectefficacy
dc.subjectTYROSINE KINASE INHIBITOR
dc.subjectGROWTH-FACTOR
dc.subjectC-KIT
dc.subjectPROGNOSTIC-FACTORS
dc.subjectIMATINIB MESYLATE
dc.subjectIN-VITRO
dc.subjectMUTATIONS
dc.subjectSU11248
dc.subjectSURVIVAL
dc.subjectTAIWANESE
dc.titleEfficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience
dc.typearticle
dspace.entity.typePublication
local.avesis.id55d307ad-d4a4-4380-ac05-68a79d87aa57
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages7
oaire.citation.endPage611
oaire.citation.issue2
oaire.citation.startPage605
oaire.citation.titleONCOLOGY LETTERS
oaire.citation.volume6
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication.latestForDiscovery059ce50a-8d16-4fc6-a86c-85c9baa19a5c

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kefeli et al. - 2013 - Efficacy of sorafenib in patients with gastrointes.pdf
Size:
364.22 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs